INSERM, a biomedical French research institute, is the sponsor of the trial. The study is led by Professor Jean-Christophe Rozé, who is working in the Nantes University Hospital in France.
INSERM: Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient’s bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields.
The TREOCAPA trial is a Proof of Viability study of the Conect4Children (c4c) project, which aims to develop a Pan European Paediatric Clinical Trial Network.
conect4children
conect4children (c4c) is a collaborative European network that aims to facilitate the development and evaluation of new drugs and other therapies for the entire paediatric population. For this, c4c endeavours to provide a platform for the efficient and swift delivery of high quality clinical trials in children and young people across all conditions and phases of the drug development process.
For these trials
c4c will use a coordinated approach to deliver high quality “regulatory grade” clinical trials in
- Multiple countries
- Multiple sites
- All paediatric age groups
by supporting
- Trial implementation using resources shared between studies
- Trial design through a combination of information about natural history, feasibility, appropriate innovation, and expert opinion
- Education and awareness within and beyond the network.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389.
The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.